RANI

Rani Therapeutics (NASDAQ:RANI) outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional milestones from its collaboration with Chugai.

SAN JOSE, Calif., Oct.

~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~ ~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~

Rani Therapeutics (NASDAQ:RANI) outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure…

~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc.

SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc.

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of…

~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity franchise beyond its existing programs, potentially adding multiple new candidates across differentiated mechanisms of action ~ SAN JOSE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc.